Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Hosted on MSN3d
Novavax to Report Q3 Earnings: Here's What to Expect
Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Outlook For Novavax
Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
KSL2d
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Hosted on MSN9d
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...
Novavax, Inc.: Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...
Business Insider1d
Novavax’s Market Share and Pipeline Uncertainties Lead to Sell Rating
J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination ...